All In Biotech

Drug Trial Radar · NCT00250445

A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)

A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 23,498 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

23,498

Actual

Start

Jan 2003

Primary completion

May 2006

Study completion May 2006

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Nov 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. It will also compare the gastrointestinal tolerability of the two medicines. The study will be conducted in patients with either rheumatoid or osteo-arthritis.

Conditions

  • Rheumatoid Arthritis,Osteoarthritis

Interventions

  • MK0663, etoricoxibDrug

  • Comparator: Diclofenac sodiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences based on combined data from this trial and MK0663 Protocols 061 & 072 (GI Tolerability in OA Patients and GI Tolerability Study in RA Patients ), respectively.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.